StockTake: Another country under the belt
Orthocell (ASX:OCC) is set to kick off sales in Germany, Austria and Switzerland for its dental guided bone and tissue regeneration product Striate+, gaining exposure to a market valued over $1 billion.
Watch the video to hear more.
This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.
This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Related Topics

SUBSCRIBE
Get the latest breaking news and stocks straight to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.